About DNA dC->dU-editing enzyme APOBEC-3F
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F) is a protein
from Homo sapiens identified by UniProt accession
Q8IUX4, 373 residues long.
MolForge cross-references it against 0 known binders and
84 disease associations.
Target properties
| Protein name | DNA dC->dU-editing enzyme APOBEC-3F |
| UniProt accession | Q8IUX4 |
| Gene | APOBEC3F |
| Organism | Homo sapiens |
| Length | 373 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (84)
Diseases linked to this target (Open Targets).
- immune deficiency, familial variable · score 0.08
- immunodeficiency 35 · score 0.07
- Chronic mucocutaneous candidosis · score 0.07
- hyper-IgM syndrome type 2 · score 0.07
- isolated agammaglobulinemia · score 0.07
- immunodeficiency, common variable, 4 · score 0.06
- hyper-IgM syndrome type 3 · score 0.06
- IgAD1 · score 0.06
- selective IgA deficiency disease · score 0.06
- severe combined immunodeficiency due to CARD11 deficiency · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IUX4-F1 | alphafold | PREDICTED | 89.19 | — |
Amino-acid sequence (373 residues)
MKPHFRNTVE RMYRDTFSYN FYNRPILSRR NTVWLCYEVK TKGPSRPRLD AKIFRGQVYS QPEHHAEMCF LSWFCGNQLP AYKCFQITWF VSWTPCPDCV AKLAEFLAEH PNVTLTISAA RLYYYWERDY RRALCRLSQA GARVKIMDDE EFAYCWENFV YSEGQPFMPW YKFDDNYAFL HRTLKEILRN PMEAMYPHIF YFHFKNLRKA YGRNESWLCF TMEVVKHHSP VSWKRGVFRN QVDPETHCHA ERCFLSWFCD DILSPNTNYE VTWYTSWSPC PECAGEVAEF LARHSNVNLT IFTARLYYFW DTDYQEGLRS LSQEGASVEI MGYKDFKYCW ENFVYNDDEP FKPWKGLKYN FLFLDSKLQE ILE
Explore DNA dC->dU-editing enzyme APOBEC-3F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets